OrthoPediatrics received FDA 510(k) clearance to market the RESPONSE 4.5/5.0mm system to treat complex scoliosis in smaller stature, younger patients. Launch is slated for 4Q18.
This new system builds on the technology of the larger RESPONSE 5.5/6.0mm version and offers a hybrid implant design, allowing either a 4.5mm rod in CoCr or 5.0mm rod in titanium or cobalt chromium/chrome, as well as multiple implant connector options and new instrumentation.
This represents the company's 26th surgical system. Three additional launches are expected within the year.
OrthoPediatrics received FDA 510(k) clearance to market the RESPONSE 4.5/5.0mm system to treat complex scoliosis in smaller stature, younger patients. Launch is slated for 4Q18. This new system builds on the technology of the larger RESPONSE 5.5/6.0mm version and offers a hybrid implant design, allowing either a 4.5mm rod in CoCr...
OrthoPediatrics received FDA 510(k) clearance to market the RESPONSE 4.5/5.0mm system to treat complex scoliosis in smaller stature, younger patients. Launch is slated for 4Q18.
This new system builds on the technology of the larger RESPONSE 5.5/6.0mm version and offers a hybrid implant design, allowing either a 4.5mm rod in CoCr or 5.0mm rod in titanium or cobalt chromium/chrome, as well as multiple implant connector options and new instrumentation.
This represents the company's 26th surgical system. Three additional launches are expected within the year.
Copy to clipboard 
